Meeting
2021 ASCO Annual Meeting
Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.
Authors
Collin M. Blakely
UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA
Collin M. Blakely , Matthew A. Gubens , Gregory M. Allen , Shrusti Shah , Matthew Jereza , Bianca Bacaltos , Sourav Bandyopadhyay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04085315
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9074)
DOI
10.1200/JCO.2021.39.15_suppl.9074
Abstract #
9074
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).
First Author: Shen Zhao
Poster
2017 ASCO Annual Meeting
A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers.
First Author: Helena Alexandra Yu
Poster
2022 ASCO Annual Meeting
Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
First Author: Jonathan W. Riess
Poster
2021 ASCO Annual Meeting
Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).
First Author: Chao Lyu